Abstract
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA
Original language | English |
---|---|
Pages (from-to) | 354-362 |
Number of pages | 9 |
Journal | Journal of Infectious Diseases |
Volume | 210 |
Issue number | 3 |
DOIs | |
Publication status | Published - Aug 1 2014 |
Keywords
- Dolutegravir
- DTG
- Elvitegravir resistance
- Integrase inhibitor
- Raltegravir resistance
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy